Holen Sie sich die Stockscreener-App
152.74
1.63%
-2.53
Handel nachbörslich:
152.39
-0.35
-0.23%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$155.27
Offen:
$156.01
24-Stunden-Volumen:
5.18M
Relative Volume:
0.71
Marktkapitalisierung:
$189.50B
Einnahmen:
$29.42B
Nettoeinkommen (Verlust:
$8.51B
KGV:
22.53
EPS:
6.7801
Netto-Cashflow:
$10.02B
1W Leistung:
-1.96%
1M Leistung:
+22.28%
6M Leistung:
+29.45%
1J Leistung:
+45.12%
1-Tages-Spanne:
$152.37
$156.01
1-Wochen-Bereich:
$150.82
$156.95
52-Wochen-Spanne:
$93.37
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, AZN, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
152.74 | 192.64B | 29.42B | 8.51B | 10.02B | 6.7801 |
|
LLY
Lilly Eli Co
|
1,020.56 | 977.37B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
244.99 | 586.40B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
228.72 | 411.55B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
AZN
Astrazeneca Plc
|
208.67 | 324.75B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
165.38 | 317.08B | 54.72B | 14.02B | 15.32B | 7.1855 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-11 | Bestätigt | Needham | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-08-19 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Hochstufung | Truist | Hold → Buy |
| 2025-07-25 | Hochstufung | Needham | Hold → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Gilead-Genhouse's $1.5B+ deal boosts synthetic lethality push - BioWorld MedTech
Gilead Sciences to Present New HIV Treatment and Prevention Data at CROI 2026 - National Today
UBS raises Gilead Sciences stock price target on HIV pipeline data - Investing.com
Mizuho Securities Lifts Gilead Sciences Price Target to $170 From $140, Maintains Outperform Rating - marketscreener.com
[Press release] Gilead to present new HIV treatment and prevention data at CROI 2026, with a focus on expanding options - European AIDS Treatment Group
Gilead Sciences, China's Qinhao Pharmaceutical Sign Global Deal for Tumor Therapy Candidate - marketscreener.com
Gilead Sciences (GILD) Secures Rights to Genhouse Bio's Cancer T - GuruFocus
Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Opti - PharmiWeb.com
Gilead’s HIV Advances And Yescarta Label Shift Refocus Investment Thesis - Yahoo Finance
Rothschild & Co Redburn Adjusts Gilead Sciences PT to $170 From $159, Maintains Buy Rating - marketscreener.com
Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options - Business Wire
5 Insightful Analyst Questions From Gilead Sciences's Q4 Earnings Call - Finviz
NEOS Investment Management LLC Has $64.06 Million Stake in Gilead Sciences, Inc. $GILD - MarketBeat
M&G PLC Has $10.82 Million Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Skandinaviska Enskilda Banken AB publ - MarketBeat
Fifth Third Bancorp Has $43.69 Million Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Investors heavily search Gilead Sciences, Inc. (GILD): Here is what you need to know - MSN
Gilead Sciences, Inc. (GILD): Investor Outlook on Robust Growth and Strategic Collaborations - DirectorsTalk Interviews
Zions Bancorporation National Association UT Has $4.46 Million Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Vanguard Group Inc. Has $13.21 Billion Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Todd Asset Management LLC Sells 22,499 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead strikes $1.5 billion cancer pact with Genhouse Bio - The Pharma Letter
Gilead Sciences, Inc. $GILD Shares Purchased by Public Sector Pension Investment Board - MarketBeat
Analyst recommendations: Eagle Materials, Coinbase Global, Gilead Sciences, Royal Gold… - marketscreener.com
5 Insightful Analyst Questions From Gilead Sciences’s Q4 Earnings Call - The Globe and Mail
Shell Asset Management Co. Sells 54,965 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
State of New Jersey Common Pension Fund D Buys 16,160 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Assetmark Inc. Acquires 28,701 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Aberdeen Group plc Sells 160,874 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
The Centrifuge Sessions: How Gilead Sciences Is Impacting Autoimmune Disease - CSRwire
PatientView Ranks Gilead “Best” at ESG - CSRwire
Gilead Sciences (GILD) Tops Earnings but Shares Fall on Guidance - GuruFocus
Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Leerink Partners Analyst Says - MarketBeat
Gilead Sciences (NASDAQ:GILD) Has Announced That It Will Be Increasing Its Dividend To $0.82 - Yahoo Finance
BTC Capital Management Inc. Buys 64,668 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Florida Financial Advisors LLC Grows Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Is Gilead Sciences Inc. stock a good pick for beginners2025 Support & Resistance & Precise Swing Trade Alerts - mfd.ru
Cookson Peirce & Co. Inc. Increases Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Cencora, Azenta, The Pennant Group, LifeStance Health Group, and Gilead Sciences Shares Are Soaring, What You Need To Know - Yahoo! Finance Canada
Can Gilead's HIV Portfolio Sustain Its Growth Trend in 2026? - The Globe and Mail
BofA Raises PT on Gilead Sciences (GILD) to $162 From $154Here's Why - Bitget
BofA Raises PT on Gilead Sciences (GILD) to $162 From $154 – Here’s Why - Insider Monkey
Focus on These 5 Stocks That Recently Hiked Dividends - TradingView
Gilead Sciences Inc (NASDAQ:GILD) Offers a Sustainable Dividend Backed by Strong Fundamentals - ChartMill
Longbow Finance SA Increases Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Just Reported And Analysts Have Been Lifting Their Price Targets - Yahoo Finance
Gilead Sciences, Inc. (NASDAQ:GILD) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Deutsche Bank Aktiengesellschaft Analyst Says - MarketBeat
TD Cowen Raises Gilead Sciences (NASDAQ:GILD) Price Target to $160.00 - MarketBeat
Varma Mutual Pension Insurance Co Has $22.71 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
ING Groep NV Trims Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.71%
0.28%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):